Matches in SemOpenAlex for { <https://semopenalex.org/work/W153303669> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W153303669 endingPage "95" @default.
- W153303669 startingPage "4789" @default.
- W153303669 abstract "Recent studies on polychemotherapy of head and neck cancer have shown an improved remission rate on adding taxanes to the standard cytotoxic drugs cisplatin and 5-fluorouracil (5-FU). Moreover, for enhancing the response rate of chemotherapy today, a series of biological response modifiers are of interest including modulators of the epidermal growth factor receptor (EGFR). Therefore we investigated whether the addition of monoclonal antibodies against the EGFR could enhance the response rate of cisplatin, 5-FU and docetaxel. Squamous cell cancer lines were transplated on nude mice. After tumors had begun to grow, they were treated either with cisplatin, 5-FU and docetaxel alone or in combination with escalating doses of a humanized monoclonal anti-EGFR antibody. Comparing with controls, docetaxel alone as well as the combination of docetaxel, cisplatin and 5-FU resulted in a significant tumor growth delay. The antibody alone also slowed down the tumor growth significantly at each concentration. Nevertheless, neither chemotherapy agents nor antibody alone yielded complete tumor remissions over an observation period up to 6 weeks. Only the combination of cisplatin, 5-FU, docetaxel and the antibody resulted in highly significant complete tumor remissions. Therefore we can show for the first time that the effect of TPF, which is now used as a novel Phase II protocol for induction chemotherapy in head and neck cancer, could be highly significantly enhanced through the addition of anti-EGFR antibodies. Because we did not observe an increased toxicity in the animal experiments, TPF/anti-EGFR therapy may define a new strategy in the induction treatment of head and neck carcinomas." @default.
- W153303669 created "2016-06-24" @default.
- W153303669 creator A5012130933 @default.
- W153303669 creator A5014106726 @default.
- W153303669 creator A5018246788 @default.
- W153303669 creator A5057108698 @default.
- W153303669 creator A5058702025 @default.
- W153303669 creator A5068158443 @default.
- W153303669 date "2004-02-26" @default.
- W153303669 modified "2023-09-23" @default.
- W153303669 title "EGFR antibody-supplemented TPE-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment." @default.
- W153303669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14981927" @default.
- W153303669 hasPublicationYear "2004" @default.
- W153303669 type Work @default.
- W153303669 sameAs 153303669 @default.
- W153303669 citedByCount "4" @default.
- W153303669 countsByYear W1533036692016 @default.
- W153303669 countsByYear W1533036692017 @default.
- W153303669 crossrefType "journal-article" @default.
- W153303669 hasAuthorship W153303669A5012130933 @default.
- W153303669 hasAuthorship W153303669A5014106726 @default.
- W153303669 hasAuthorship W153303669A5018246788 @default.
- W153303669 hasAuthorship W153303669A5057108698 @default.
- W153303669 hasAuthorship W153303669A5058702025 @default.
- W153303669 hasAuthorship W153303669A5068158443 @default.
- W153303669 hasConcept C121608353 @default.
- W153303669 hasConcept C126322002 @default.
- W153303669 hasConcept C143998085 @default.
- W153303669 hasConcept C159654299 @default.
- W153303669 hasConcept C203014093 @default.
- W153303669 hasConcept C2776530083 @default.
- W153303669 hasConcept C2776694085 @default.
- W153303669 hasConcept C2778239845 @default.
- W153303669 hasConcept C2779438470 @default.
- W153303669 hasConcept C2780456651 @default.
- W153303669 hasConcept C2781190966 @default.
- W153303669 hasConcept C502942594 @default.
- W153303669 hasConcept C542903549 @default.
- W153303669 hasConcept C71924100 @default.
- W153303669 hasConceptScore W153303669C121608353 @default.
- W153303669 hasConceptScore W153303669C126322002 @default.
- W153303669 hasConceptScore W153303669C143998085 @default.
- W153303669 hasConceptScore W153303669C159654299 @default.
- W153303669 hasConceptScore W153303669C203014093 @default.
- W153303669 hasConceptScore W153303669C2776530083 @default.
- W153303669 hasConceptScore W153303669C2776694085 @default.
- W153303669 hasConceptScore W153303669C2778239845 @default.
- W153303669 hasConceptScore W153303669C2779438470 @default.
- W153303669 hasConceptScore W153303669C2780456651 @default.
- W153303669 hasConceptScore W153303669C2781190966 @default.
- W153303669 hasConceptScore W153303669C502942594 @default.
- W153303669 hasConceptScore W153303669C542903549 @default.
- W153303669 hasConceptScore W153303669C71924100 @default.
- W153303669 hasIssue "6C" @default.
- W153303669 hasLocation W1533036691 @default.
- W153303669 hasOpenAccess W153303669 @default.
- W153303669 hasPrimaryLocation W1533036691 @default.
- W153303669 hasRelatedWork W157421111 @default.
- W153303669 hasRelatedWork W1990897966 @default.
- W153303669 hasRelatedWork W2061800353 @default.
- W153303669 hasRelatedWork W2094938224 @default.
- W153303669 hasRelatedWork W2240675528 @default.
- W153303669 hasRelatedWork W2411515331 @default.
- W153303669 hasRelatedWork W2416358629 @default.
- W153303669 hasRelatedWork W2460567964 @default.
- W153303669 hasRelatedWork W4230595185 @default.
- W153303669 hasRelatedWork W4237179769 @default.
- W153303669 hasVolume "23" @default.
- W153303669 isParatext "false" @default.
- W153303669 isRetracted "false" @default.
- W153303669 magId "153303669" @default.
- W153303669 workType "article" @default.